quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:28:12·57d
SECFiling
Protagonist Therapeutics Inc. logo

SEC Form 10-K filed by Protagonist Therapeutics Inc.

PTGX· Protagonist Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • PTGX
    Protagonist Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Sep 17UpdateBarclays$72.00
  • Sep 12UpdateLeerink Partners$73.00
  • Jun 17UpdateCitigroup$72.00
  • Dec 6UpdateGoldman$47.00
  • Dec 6UpdateBMO Capital Markets$62.00
  • Nov 5UpdateWedbush$58.00

Related

  • INSIDER2d
    SEC Form 4 filed by Ali Asif
  • NEWS7d
    Protagonist Therapeutics Reports Granting of Inducement Awards
  • NEWS26d
    Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
  • INSIDER27d
    SEC Form 4 filed by Molina Arturo Md
  • INSIDER27d
    SEC Form 4 filed by Selick Harold E
  • INSIDER27d
    SEC Form 4 filed by Ali Asif
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Protagonist Therapeutics Inc.
  • SEC28d
    SEC Form 144 filed by Protagonist Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022